Inspire Medical has spent years building a compelling sleep apnea device story, but Bank of America says the stock now faces ...

Inspire reported quarterly revenue of $204.6 million and an adjusted diluted earnings per share of $0.10. Both of these ...

Nyxoah (NASDAQ:NYXH) reported 13% sequential worldwide net revenue growth in the first quarter of 2026, driven primarily by continued adoption of its Genio system in the United States, where the ...

One of the key conclusions in EY’s 19th annual Pulse of the MedTech Industry Report is that the global medical technology ...

Sleep breathing disorders (SBDs)—including obstructive sleep apnoea, central sleep apnoea and sleep-related hypoventilation syndromes—represent a major yet under-recognised contributor to global ...

Nyxoah Sa () has held its Q1 earnings call. Read on for the main highlights of the call. Meet Samuel – Your Personal Investing Prophet. Start a conversation with TipRanks’ tru ...

By Dr Abdulmohsen Ebrahim AlterkiIn the past, sleep related breathing disorders were often considered minor or simply a nighttime nuisance. However, modern medicine has revealed that many of these ...

Outgoing Nyxoah CEO Olivier Taelman [Image from LinkedIn] Nyxoah announced today that it plans to move on from current CEO Olivier Taelman and begin a search for a new chief executive.

Pulsetto and Truvaga are closer to clinical neurostimulation devices, while Apollo is described as a sensory-based wearable ...

Ever feel so stressed you're equal parts wired and tired? Busy, modern life means many of us live stuck in a "fight or flight" state, even when we're safe. Luckily, it's possible to get back into ...